Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 20, 2025.

via HealthDay

FRIDAY, June 20, 2025 -- For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and cardiovascular event risks, according to a study published online June 17 in the Annals of Internal Medicine.

Anum Saeed, M.D., from the University of Pittsburgh, and colleagues compared mortality and cardiovascular event risks in patients treated with semaglutide versus empagliflozin and dulaglutide versus empagliflozin in target trial emulation studies. Patients aged 45 years or older with type 2 diabetes treated from Jan. 1, 2019, to Dec. 31, 2024, with semaglutide, dulaglutide, or empagliflozin were included in the study.

The researchers found that the rates of the composite of death, myocardial infarction (MI), or stroke were 3.7 and 4.5 percent at two years for patients treated with semaglutide and empagliflozin (7,899 and 7,899 patients), respectively, and 5.9 versus 6.9 percent at three years. For the composite outcome, the corresponding incidence rates were 20.99 versus 23.56 per 1,000 person-years, with a hazard ratio of 0.98 (95 percent confidence interval, 0.78 to 1.02). For the individual outcomes of death, MI, and stroke, the hazard ratios (95 percent confidence intervals) were 0.97 (0.81 to 1.15), 0.85 (0.68 to 1.05), and 0.62 (0.43 to 0.89), respectively. For the composite outcome and for death, MI, and stroke separately, the risks for dulaglutide- and empagliflozin-treated patients were similar.

"The apparent modest treatment benefit of semaglutide over empagliflozin coincided with modest greater reductions in weight and HbA1c within the first year of use," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-21 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords